Burkholderia Infections - Pipeline Review, H1 2016

  • ID: 3783291
  • Report
  • 76 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Arno Therapeutics, Inc.
  • Bavarian Nordic A/S
  • Eumedica SA
  • Grifols, S.A.
  • NanoBio Corporation
  • Soligenix, Inc.
  • MORE
Burkholderia Infections - Pipeline Review, H1 2016

Summary

‘Burkholderia Infections - Pipeline Review, H1 2016’, provides an overview of the Burkholderia Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Burkholderia Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burkholderia Infections and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Burkholderia Infections
- The report reviews pipeline therapeutics for Burkholderia Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Burkholderia Infections therapeutics and enlists all their major and minor projects
- The report assesses Burkholderia Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Burkholderia Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Burkholderia Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Burkholderia Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Arno Therapeutics, Inc.
  • Bavarian Nordic A/S
  • Eumedica SA
  • Grifols, S.A.
  • NanoBio Corporation
  • Soligenix, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Burkholderia Infections Overview

Therapeutics Development

Pipeline Products for Burkholderia Infections - Overview

Pipeline Products for Burkholderia Infections - Comparative Analysis

Burkholderia Infections - Therapeutics under Development by Companies

Burkholderia Infections - Therapeutics under Investigation by Universities/Institutes

Burkholderia Infections - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Burkholderia Infections - Products under Development by Companies

Burkholderia Infections - Products under Investigation by Universities/Institutes

Burkholderia Infections - Companies Involved in Therapeutics Development

Arno Therapeutics, Inc.

Bavarian Nordic A/S

Emergent BioSolutions Inc.

Eumedica SA

Grifols, S.A.

NanoBio Corporation

Sarepta Therapeutics, Inc.

Soligenix, Inc.

Syntiron LLC

TGV-Laboratories

Vault Pharma Inc.

Burkholderia Infections - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

Antisense Oligonucleotide to Inhibit AcpP for Burkholderia Cepacia Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotide to Inhibit Nucleoporin p62 for Burkholderia Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AR-13 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARD-3100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARD-3150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Burkholderia pseudomallei vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Burkholderia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Burkholderia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dusquetide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EV-035 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GC-072 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melioidosis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mul-1867 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SGX-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SGX-943 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit InhA for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

temocillin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPI-231 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Burkholderia Infections - Dormant Projects

Burkholderia Infections - Discontinued Products

Burkholderia Infections - Product Development Milestones

Featured News & Press Releases

May 31, 2016: FDA Grants Soligenix “Fast Track” Designation for SGX943 for the Treatment of Melioidosis

Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC

Aug 14, 2014: US DTRA to fund preclinical work on Evolva’s antibiotic GC-072

Feb 21, 2014: Bavarian Nordic’s MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development

Feb 21, 2014: Bavarian Nordic’s MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development

Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis

Sep 10, 2012: Evolva Presents Preclinical Data On EV-035 At ICAAC

Oct 15, 2009: NanoBio’s Nanoemulsion Kills Drug-Resistant Bacteria Found In Cystic Fibrosis Patients

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Burkholderia Infections, H1 2016

Number of Products under Development for Burkholderia Infections - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Burkholderia Infections - Pipeline by Arno Therapeutics, Inc., H1 2016

Burkholderia Infections - Pipeline by Bavarian Nordic A/S, H1 2016

Burkholderia Infections - Pipeline by Emergent BioSolutions Inc., H1 2016

Burkholderia Infections - Pipeline by Eumedica SA, H1 2016

Burkholderia Infections - Pipeline by Grifols, S.A., H1 2016

Burkholderia Infections - Pipeline by NanoBio Corporation, H1 2016

Burkholderia Infections - Pipeline by Sarepta Therapeutics, Inc., H1 2016

Burkholderia Infections - Pipeline by Soligenix, Inc., H1 2016

Burkholderia Infections - Pipeline by Syntiron LLC, H1 2016

Burkholderia Infections - Pipeline by TGV-Laboratories, H1 2016

Burkholderia Infections - Pipeline by Vault Pharma Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Burkholderia Infections - Dormant Projects, H1 2016

Burkholderia Infections - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Burkholderia Infections, H1 2016

Number of Products under Development for Burkholderia Infections - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Arno Therapeutics, Inc.
  • Bavarian Nordic A/S
  • Eumedica SA
  • Grifols, S.A.
  • NanoBio Corporation
  • Soligenix, Inc.
  • MORE
Burkholderia Infections Burkholderia infections are caused by Burkholderia cepacia bacteria. Symptoms include low-grade fever, progressing to much more serious conditions, including pneumonia, cough, congestion, shortness of breath, and wheezing. Predisposing factors include weakened immune system and lung diseases. Treatment includes antibiotics.

Burkholderia Infections pipeline therapeutics constitutes close to 19 molecules. Out of which approximately 15 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 13 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Our latest report Burkholderia Infections – Pipeline Review, H1 2016, outlays comprehensive information on the therapeutics under development for Burkholderia Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Burkholderia Infections and features dormant and discontinued projects.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
Arno Therapeutics, Inc.
Bavarian Nordic A/S
Emergent BioSolutions Inc.
Eumedica SA
Grifols, S.A.
NanoBio Corporation
Sarepta Therapeutics, Inc.
Soligenix, Inc.
Syntiron LLC
TGV-Laboratories
Vault Pharma Inc.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll